Clinical Outcomes After Same-Agent Double-Dose Anti-VEGF Escalation in Eyes with a Suboptimal Response to Standard-Dose Treatment for Exudative Macular Diseases: A Real-World Pre–Post Study
Qiumei Gu, Hongyi Liu, Yifan Xie, Fang Lu, Ziyan He, Yilong Chen, Jiacen Wan, Xiaoshuang Jiang · 2026
Read Clinical Outcomes After Same-Agent Double-Dose Anti-VEGF Escalation in Eyes with a Suboptimal Response to Standard-Dose Treatment for Exudative Macular Diseases: A Real-World Pre–Post Study by Qiumei Gu, Hongyi Liu, Yifan Xie, Fang Lu, Ziyan He, Yilong Chen, Jiacen Wan, Xiaoshuang Jiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13466651.txt.
Description
Qiumei Gu and colleagues review eyes with wet macular disease that responded poorly to standard injections and were switched to double doses of the same drug, in a 2026 real-world study. The drugs block a vessel growth factor that drives leaking in the back of the eye. Eyes qualified only after at least three standard injections left active leaking or swelling.
Vision change and retinal anatomy after the switch form the main outcomes, with injection spacing as a secondary measure. Records captured the full treatment history, so the escalation decision reflects real clinic judgment rather than trial rules. Evidence for this doubling strategy has been thin, which is the gap the authors set out to fill.
Catalog record
| CREATOR | Qiumei Gu, Hongyi Liu, Yifan Xie, Fang Lu, Ziyan He, Yilong Chen, Jiacen Wan, Xiaoshuang Jiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |